Charles William Ernest Tomlinson

Charles William Ernest Tomlinson

Auto-generated profile, based on publicly available information

Charles William Ernest Tomlinson

Department of Biology, University of York, York, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2024 in Applied Research
Verified
Journal Article
Open access
DFDaren Fearon
Daren Fearon
APAilsa Powell
Ailsa Powell
ADAlice Douangamath
Alice Douangamath
ADAlexandre Dias
Alexandre Dias
CTCharles W. E. Tomlinson
Charles W. E. Tomlinson
FDFrank von Delft
Frank von Delft
Fragment‐based drug discovery is a well‐established method for the identification of chemical starting points for development into clinical candidates. Historically, crystallographic fragment screening was perceived to be low‐throughput and time consuming. However, thanks to advances in synchrotron capabilities and the introduction of dedicated facilities, such as the XChem platform at Diamond Light Source, there have been substantial improvements in throughput and integration between sample preparation, data collection and hit identification. Herein we share our experiences of establishing a crystallographic fragment screening facility, our learnings from operating a user programme for ten years and our perspective on applying structural enablement to rapidly progress initial fragment hits to lead‐like molecules.

25 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMartin Schwalm
Martin Schwalm
JDJohannes Dopfer
Johannes Dopfer
AKAdarsh Kumar
Adarsh Kumar
FGFrancesco A. Greco
Francesco A. Greco
NBNicolas Bauer
Nicolas Bauer
VRVladimir Rogov
Vladimir Rogov
Recent successes in developing small molecule degraders that act through the ubiquitin system have spurred efforts to extend this technology to other mechanisms, including the autophagosomal-lysosomal pathway. Therefore, reports of autophagosome tethering compounds (ATTECs) have received considerable attention from the drug development community. ATTECs are based on the recruitment of targets to LC3/GABARAP, a family of ubiquitin-like proteins that presumably bind to the autophagosome membrane and tether cargo-loaded autophagy receptors into the autophagosome. In this work, we rigorously tested the target engagement of the reported ATTECs to validate the existing LC3/GABARAP ligands. Surprisingly, we were unable to detect interaction with their designated target LC3 using a diversity of biophysical methods. Intrigued by the idea of developing ATTECs, we evaluated the ligandability of LC3/GABARAP by in silico docking and large-scale crystallographic fragment screening. Data based on approximately 1000 crystal structures revealed that most fragments bound to the HP2 but not to the HP1 pocket within the LIR docking site, suggesting a favorable ligandability of HP2. Through this study, we identified diverse validated LC3/GABARAP ligands and fragments as starting points for chemical probe and ATTEC development.

1 February 2019 in ACS Chemical Biology
Verified
Journal Article
Open access
DCDavid Chisholm
David Chisholm
CTCharles W. E. Tomlinson
Charles W. E. Tomlinson
GZGarr-Layy Zhou
Garr-Layy Zhou
CHClaire Holden
Claire Holden
VAValerie Affleck
Valerie Affleck
EPEhmke Pohl
Ehmke Pohl
Retinoids, such as all-trans-retinoic acid (ATRA), are endogenous signalling molecules derived from Vitamin A that influ-ence a variety of cellular processes through mediation of transcription events in the cell nucleus. Due to these wide-ranging and powerful biological activities, retinoids have emerged as therapeutic candidates of enormous potential. However, their use has been limited, to date, due to a lack of understanding of the complex and intricate signaling pathways that they con-trol. We have designed and synthesized a family of synthetic retinoids that exhibit strong, intrinsic, solvatochromatic fluo-rescence as multifunctional tools to interrogate these important biological activities. We utilized the unique photophysical characteristics of these fluorescent retinoids to develop a novel in vitro fluorometric binding assay to characterize and quanti-fy their binding to their cellular targets, including Cellular Retinoid Binding Protein II (CRABPII). The dihydroquinoline retinoid, DC360, exhibited particularly strong binding (Kd = 34.0 ± 2.5 nM) and we further used X-ray crystallography to solve the structure of the DC360-CRABPII complex to 1.8 Å, which showed that DC360 occupies the known hydrophobic retinoid-binding pocket. Finally, we used confocal fluorescence microscopy to image the cellular behaviour of the com-pounds in cultured human epithelial cells, highlighting a fascinating nuclear localisation, and used RNA sequencing to con-firm that the compounds regulate similar cellular processes to ATRA. We anticipate that the unique properties of these fluo-rescent retinoids can now be used to shed new light on the vital and highly complex retinoid signalling pathway.

1 January 2020
Verified
Book Chapter
Closed access
EPEhmke Pohl
Ehmke Pohl
CTCharles W E Tomlinson
Charles W E Tomlinson

8 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
XNXiaomin Ni
Xiaomin Ni
RRR. Blake Richardson
R. Blake Richardson
AGAndre Godoy
Andre Godoy
MFMatteo P. Ferla
Matteo P. Ferla
CKCaroline Kikawa
Caroline Kikawa
FDFrank von Delft
Frank von Delft
The Zika viral protease NS2B-NS3 is essential for the cleavage of viral polyprotein precursor into individual structural and non-structural (NS) proteins and is therefore an attractive drug target. Generation of a robust crystal system of co-expressed NS2B-NS3 protease has enabled us to perform a crystallographic fragment screening campaign with 1076 fragments. 46 fragments with diverse scaffolds are identified to bind in the active site of the protease, with another 6 fragments observed in a potential allosteric site. To identify binding sites that are intolerant to mutation and thus suppress the outgrowth of viruses resistant to inhibitors developed from bound fragments, we perform deep mutational scanning of the NS2B-NS3 protease. Merging fragment hits yields an extensive set of ‘mergers’, defined as synthetically accessible compounds that recapitulate constellations of observed fragment-protein interactions. In addition, the highly sociable fragment hits enable rapid exploration of chemical space via algorithmic calculation and thus yield diverse possible starting points. In this work, we maximally explore the binding opportunities to NS2B-NS3 protease, facilitating its resistance-resilient antiviral development.

9 November 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
CTCharles W. E. Tomlinson
Charles W. E. Tomlinson
DCDavid Chisholm
David Chisholm
RVRoy Valentine
Roy Valentine
AWAndrew Whiting
Andrew Whiting
EPEhmke Pohl
Ehmke Pohl
Vitamin A derived retinoid compounds have multiple, powerful roles in the cellular growth and development cycle and, as a result, have attracted significant attention from both academic and pharmaceutical research in developing and characterizing synthetic retinoid analogues. Simplifying the hit development workflow for retinoid signaling will improve options available for tackling related pathologies, including tumor growth and neurodegeneration. Here, we present a novel assay that employs an intrinsically fluorescent synthetic retinoid, DC271, which allows direct measurement of the binding of nonlabeled compounds to relevant proteins. The method allows for straightforward initial measurement of binding using existing compound libraries and is followed by calculation of binding constants using a dilution series of plausible hits. The ease of use, high throughput format, and measurement of both qualitative and quantitative binding offer a new direction for retinoid-related pharmacological development.